Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00522210
Recruitment Status : Completed
First Posted : August 29, 2007
Last Update Posted : September 3, 2014
Information provided by (Responsible Party):
Josephine Ho, University of Calgary

Brief Summary:
The purpose of this study is to determine whether there is a difference in blood sugar control (as measured by hemoglobin A1c (HA1c)), in children given twice daily insulin injections incorporating a new long acting insulin analogue (detemir) compared to children using their current three times a day insulin injections (with intermediate and rapid acting insulin).

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Drug: Detemir Other: Novolin NPH or Humulin N Not Applicable

Detailed Description:

Children with type 1 diabetes (DM1) can only be treated with subcutaneous insulin at the present time in Canada. It has been shown that intensive insulin treatment using at least three times daily (TID) insulin injections achieves superior blood glucose control with less long term complications of diabetes than conventional insulin treatment using once daily (OD) or twice daily (BID) insulin injections. However, many patients find it difficult to adhere to TID insulin injections since it is an invasive and painful therapy, which results in frequent insulin omission.

This study is a randomized controlled open-labeled non-inferiority trial to compare the glycemic control as measured by HbA1c after 6 months of a BID insulin regimen using detemir insulin, or the currently used TID insulin with intermediate acting insulin (Novolin NPH or Humulin N). Patients will be randomized to either the active control group (standard TID regimen) or the treatment group (BID regimen with new long acting insulin analogue). A run-in period of 1 month will be used to facilitate the change in insulin regimen. Insulin doses will be adjusted by weekly phone contact with the research nurse for one month prior to baseline blood work. Patients will continue on the same diet and exercise routine as recommended by their usual diabetes team. They will also be seen every 3 months by the research nurse to review blood glucose, assess height and weight and arrange for blood work to be done in conjunction with their routine bloodwork. All patients will continue to be seen by their usual diabetologist, nurse, and dietician at their regularly scheduled clinic visits (every 3 months).

Outcomes include: HA1c between groups at 6 months (surrogate marker of metabolic control for diabetes measured through a venous or capillary blood sample), frequency of adverse events (severe hypoglycemia, mild hypoglycemia, episodes of diabetic ketoacidosis, weight gain), diabetes quality of life for youth (DQOL).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparison of Insulin Detemir in a BID Insulin Regimen Versus a TID Insulin Regimen in Children With Type 1 Diabetes: A Randomized Controlled Trial
Study Start Date : March 2008
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: BID insulin with LA analogue
Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
Drug: Detemir
Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
Other Name: Levemir

Active Comparator: Standard TID insulin
Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
Other: Novolin NPH or Humulin N
Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.

Primary Outcome Measures :
  1. Hemoglobin A1C [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Number of episodes of hypoglycemia (severe and mild) [ Time Frame: 6 months ]
  2. Number of episodes of diabetic ketoacidosis (DKA) [ Time Frame: 6 months ]
  3. Body Mass Index (BMI) kg/m2 [ Time Frame: 6 months ]
  4. Diabetes Quality of Life Questionaire-youth version [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Children with DM1 6-17 years old that are currently on a TID regimen of insulin with rapid acting insulin and intermediate acting insulin.
  2. Currently being followed at the Alberta Children's Hospital Diabetes Clinic.
  3. Duration of diabetes of at least 12 months.

Exclusion Criteria:

  1. Children younger than 6 years of age will be excluded since long-acting analogue has not been approved in children younger than 6 years old.
  2. Children with compromised metabolic control (HA1c greater than 10%).
  3. Children with other chronic underlying medical conditions that could affect glycemic control i.e. uncontrolled hypothyroidism, hyperthyroidism, celiac disease, etc.
  4. Language or psychosocial barrier preventing the family from completing the study.
  5. Diabetes duration of less than 12 months.
  6. Participation in other clinical trials with specified clinic visit schedule.
  7. Patients currently on insulin pump therapy or multiple daily injections of greater than three injections per day.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00522210

Layout table for location information
Canada, Alberta
Alberta Children's Hospital
Calgary, Alberta, Canada, T3B 6A8
Sponsors and Collaborators
University of Calgary
Layout table for investigator information
Principal Investigator: Josephine Ho, MD University of Calgary
Publications of Results:
Layout table for additonal information
Responsible Party: Josephine Ho, Pediatric Endocrinologist, University of Calgary Identifier: NCT00522210    
Other Study ID Numbers: E-20635
First Posted: August 29, 2007    Key Record Dates
Last Update Posted: September 3, 2014
Last Verified: March 2011
Keywords provided by Josephine Ho, University of Calgary:
type 1 diabetes
long acting insulin analogue
hemoglobin A1c
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Isophane Insulin, Human
Hypoglycemic Agents
Physiological Effects of Drugs